Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

Not specified

Primary Completion Date

September 30, 2008

Conditions
InfluenzaVirus Diseases
Interventions
BIOLOGICAL

H2N2 1960 AA ca recombinant vaccine

Approximately 0.2 ml of 10\^7 TCID50 doses of vaccine administered intranasally

Trial Locations (1)

21205

Johns Hopkins Bayview Medical Center, CIR Unit at the Mason F Lord Building, Baltimore

All Listed Sponsors
collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00722774 - Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine | Biotech Hunter | Biotech Hunter